Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 9, 2011, Pages 3510-3515

  Chen, Ming Wei ^a,b   Liao, Hsin Yu ^a,b   Huang, Yaoxing ^c   Jan, Jia Tsrong ^b   Huang, Chih Cheng ^d   Ren, Chien Tai ^b   Wu, Chung Yi ^b   Cheng, Ting Jen Rachel ^b   Ho, David D ^c   Wong, Chi Huey ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c ROCKEFELLER UNIVERSITY   (United States)

^d FISHERIES RESEARCH INSTITUTE   (Taiwan)

Author keywords

Genotype; Serotype

Indexed keywords

CROSS REACTING ANTIBODY; DNA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CLADISTICS; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ELECTROPORATION; FEMALE; GENE MUTATION; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; VACCINATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; ANTIGENS, VIRAL; CARBOHYDRATE METABOLISM; CELL LINE; CROSS PROTECTION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNE SERA; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MICROARRAY ANALYSIS; MOLECULAR SEQUENCE DATA; MUTATION; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; POLYSACCHARIDES; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, VIRUS; VACCINES, DNA;

ANIMALIA; MUS; ORTHOMYXOVIRIDAE;

EID: 79952757247     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1019744108     Document Type: Article

References (44)

1. Chen MW, et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA 105:13538-13543.
2. Bodles-Brakhop AM, Heller R, Draghia-Akli R (2009) Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 17:585-592.
3. Liu M, et al. (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101(Suppl 2):14567-14571.
4. Laddy DJ, et al. (2007) Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25:2984-2989. (Pubitemid 46482729)
5. Tao P, et al. (2009) Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Antiviral Res 81:253-260.
6. Kaiser J (2006) A one-size-fits-all flu vaccine? Science 312:380-382.
7. Nicholson KG, Wood JM, Zambon M (2003) Influenza. Lancet 362:1733-1745. (Pubitemid 37468326)
8. Jeon SH, Arnon R (2002) Immunization with influenza virus hemagglutinin globular region containing the receptor-binding pocket. Viral Immunol 15:165-176. (Pubitemid 34273446)
9. Yewdell JW, Webster RG, Gerhard WU (1979) Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. Nature 279:246-248. (Pubitemid 9160009)
10. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 69:531-569.
11. Kaverin NV, et al. (2002) Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol 83:2497-2505.
12. Smith DJ, et al. (2004) Mapping the antigenic and genetic evolution of influenza virus. Science 305:371-376. (Pubitemid 38938148)
13. Matrosovich M, et al. (2000) Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol 74:8502-8512. (Pubitemid 30666701)
14. Connor RJ, Kawaoka Y, Webster RG, Paulson JC (1994) Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology 205:17-23. (Pubitemid 24360586)
15. Vines A, et al. (1998) The role of influenza A virus hemagglutinin residues 226 and 228 in receptor specificity and host range restriction. J Virol 72:7626-7631. (Pubitemid 28377900)
16. Glaser L, et al. (2005) A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol 79:11533-11536. (Pubitemid 41170697)
17. Stevens J, et al. (2006) Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol 355:1143-1155. (Pubitemid 43012153)
18. Hoffmann E, Lipatov AS,Webby RJ, Govorkova EA, Webster RG (2005) Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 102:12915-12920. (Pubitemid 41279464)
19. Hensley SE, et al. (2009) Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326:734-736.
20. Jin H, et al. (2005) Two residues in the hemagglutinin of A/Fujian/411/02-like influenza viruses are responsible for antigenic drift fromA/Panama/2007/99. Virology 336:113-119. (Pubitemid 40603676)
21. Stevens J, et al. (2006) Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312:404-410.
22. Yang ZY, et al. (2007) Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317:825-828.
23. Skehel JJ, et al. (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA 81:1779-1783. (Pubitemid 14149547)
24. Matrosovich M, Zhou N, Kawaoka Y, Webster R (1999) The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol 73:1146-1155. (Pubitemid 29036766)
25. Dong J, et al. (2009) Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production. Influenza Other Respi Viruses 3:287-295.
26. Gamblin SJ, et al. (2004) The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303:1838-1842. (Pubitemid 38374870)
27. Philpott M, Hioe C, Sheerar M, Hinshaw VS (1990) Hemagglutinin mutations related to attenuation and altered cell tropism of a virulent avian influenza A virus. J Virol 64:2941-2947. (Pubitemid 20171286)
28. Philpott M, Easterday BC, Hinshaw VS (1989) Neutralizing epitopes of the H5 hemagglutinin from a virulent avian influenza virus and their relationship to pathogenicity. J Virol 63:3453-3458. (Pubitemid 19181406)
29. Stevens J, et al. (2008) Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol 381:1382-1394.
30. Wang CC, et al. (2009) Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci USA 106:18137-18142.
31. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417-427. (Pubitemid 13178866)
32. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289:373-378.
33. Landry SJ (2008) Three-dimensional structure determines the pattern of CD4+ T-cell epitope dominance in influenza virus hemagglutinin. J Virol 82:1238-1248.
34. Sweetser MT, Braciale VL, Braciale TJ (1989) Class I major histocompatibility complex-restricted T lymphocyte recognition of the influenza hemagglutinin. Overlap between class I cytotoxic T lymphocytes and antibody sites. J Exp Med 170:1357-1368. (Pubitemid 19250699)
35. Sinnathamby G, Eisenlohr LC (2003) Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification. J Immunol 170:3504-3513. (Pubitemid 36359216)
36. Leroux-Roels I, et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 370:580-589. (Pubitemid 47247854)
37. Leroux-Roels I, et al. (2008) Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3:e1665.
38. Mahmood K, et al. (2008) H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26:5393-5399.
39. Haynes JR, et al. (2009) Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.Vaccine 27:530-541.
40. Potter CW, Oxford JS (1979) Determinants of immunity to influenza infection in man. Br Med Bull 35:69-75. (Pubitemid 9096975)
41. Rowe T, et al. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37:937-943. (Pubitemid 29140593)
42. Luxembourg A, Evans CF, Hannaman D (2007) Electroporation-based DNA immunisation: Translation to the clinic. Expert Opin Biol Ther 7:1647-1664. (Pubitemid 350161649)
43. He J, et al. (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69:6705-6711.
44. Hall TA (1999) BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 41:95-98.